Accordingly, the novel therapeutic approach for CRPC patients of targeting the Akt or β-catenin signaling pathway in prostate cancer cells could potentially improve the effectiveness of CRPC treatments [12]. The gene discussed is AKT1; the disease is prostate cancer.